Abstract Each year, 11 million patients present in the USA with new symptoms suggestive of obstructive coronary artery disease (CAD). Most undergo stress testing but <10 % demonstrate myocardial ischemia. Moreover, up to 60 % will have CAD which adversely affects outcomes. Cardiac computed tomography (CCT) is being used increasingly as an alternative to stress testing to rule out obstructive CAD in symptomatic patients, and large cohort studies in asymptomatic patients have identified burden of coronary atherosclerosis as a predictor of major adverse cardiovascular events (MACE). This review article will critically evaluate major clinical studies on the use of CCT in both symptomatic and asymptomatic patients and discuss the lessons for the clinical use of CCT.
Introduction
Cardiac computed tomography (CCT), due to the revolutionary development in hardware and software and resulting improved image quality with reduced radiation doses, has become a viable alternative to assess for coronary artery disease (CAD) [1] . Since its introduction in 2001, CCT has been an area of very active research with large cohort studies in asymptomatic patients, registries for stable chest pain and randomized trials for acute chest pain syndromes. This review provides a critical appraisal of the major studies of the use of CCT and their potential clinical impact on patient management.
Traditional Imaging to Improve Management of Coronary Artery Disease
In the USA, about 11 million patients [2] , among them 4 million de novo [3] , present annually with symptoms suggestive of obstructive CAD, such as chest pain or dyspnea on exertion, making this one of the most common patient presentations. The ability of traditional cardiovascular risk factors and clinical presentation to discriminate those with and without ischemic heart disease is limited [4] . For example, the Diamond and Forrester classification [5] significantly overestimates the likelihood of obstructive CAD (predicted vs. observed prevalence of obstructive CAD, 42 vs. 10 %; p<0.001) in both patients with atypical and typical angina (37 and 71 % vs. 7 and 19 %, respectively, both p<0.001) [6] . As a result, most symptomatic patients undergo noninvasive functional testing for further evaluation, including standard exercise treadmill testing (ETT), nuclear myocardial perfusion imaging with single-photon emission computed tomography (SPECT), and stress echocardiography. These functional tests are designed to provoke myocardial ischemia by using exercise or pharmacological stress agents either to increase myocardial work and oxygen demand or to induce vasodilation-elicited heterogeneity in induced coronary flow. An abnormal ETT is typically defined as ST changes consistent with ischemia, a positive SPECT is defined as inducible ischemia in at least one coronary territory, and a positive stress echo as ischemia with wall motion abnormality during stress in at least one coronary territory. Most data on the diagnostic accuracy of these tests stem from clinical referral populations. In meta-analyses, high sensitivities have been reported for image-based stress testing (SPECT 87 % and echocardiography 86 %) with lower sensitivity for ETT (68 %). In contrast, specificity is moderate across modalities (SPECT, 73 %; echocardiography, 81 %; ETT, 77 %) [7] [8] [9] . After adjustment for referral, however, specificities further decrease below 40 % [10] [11] [12] . Consequently more than half of subsequently performed invasive coronary angiograms do not demonstrate flow-limiting stenosis [13] . Overall, the work-up of nearly 90 % of symptomatic patients undergoing noninvasive diagnostic testing for obstructive CAD does not demonstrate myocardial ischemia or a flow-limiting stenosis in invasive angiography [8, 9, 11, 14] . Stress testing also does not detect coronary atherosclerosis that is non-flow limiting, which is present in approximately 60 % of these patients [15••] .
Cardiac CT
Over the past two decades, computed tomography (CT) has rapidly evolved. Contemporary scanners acquire 64-320 cross-sections per rotation, depicting vascular details with a spatial resolution <0.5 mm. Faster rotation, efficient reconstruction algorithms, or multiple X-ray sources allow very fast imaging, and combined with heart rate-reducing medication, it is now possible to image the coronary arteries without motion artifacts in most patients. ECG-synchronized, contrastenhanced images of the heart and coronary artery vessels can be acquired in one to five heartbeats. CCT has evolved into a robust and reliable technique for detection and assessment of coronary stenosis and atherosclerotic plaque. The radiation exposure has dramatically decreased over the past years, and doses <5 mSv are now common practice at leading centers and doses of 10 mSv or less are seen in large registries. While the use of CCT is growing, it is still underutilized in comparison to functional tests. In the USA, stress myocardial perfusion imaging by SPECT is performed 50 times more frequently than CCT. Given the direct coronary visualization, CCT appears as an attractive diagnostic alternative to functional testing.
Multicenter Trials to Determine Accuracy to Detect Nonobstructive and Obstructive CAD
In meta-analyses of a large number of single-center trials, CCT has been established as a noninvasive diagnostic test with excellent sensitivity (97.2; 95 % confidence interval [CI], 96.2 to 98.0 %) and very good specificity (87.4 %; 95 % CI, 84.5 to 89.8 %) for the detection of >50 % coronary artery stenosis as compared to the gold standard invasive coronary angiography [16] . Several prospective multicenter studies [1, 3, 17] have confirmed these results (Table 1) . For example, the Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography (ACCURACY) trial reported a sensitivity of 95 % and a specificity of 83 % for the detection of obstructive CAD. ACCURACY is most relevant to clinicians because the prevalence of CAD (25 %) and the CT technology used (64 slice) represent a common clinical scenario. The CORE 64 trial was an exception; the reported sensitivity was lower than the specificity. This was explained by a higher threshold to diagnose obstructive CAD [3] . Studies using newer CT technology suggest that the technological improvements are used to lower radiation dose to sub-millisievert levels while maintaining excellent sensitivity and good specificity [18•] . Most commonly, a non-contrast coronary artery calcium scan is obtained prior to the CCT and studies have reported lower specificity of 50 % in patients with an Agatston score (AS) >400. In clinical practice, patients do not often go onto a CCT if the AS is >800 and the scan is performed with 64 slice technology.
Very intriguing are the results of two studies using fractional flow reserve (FFR) as determined in invasive coronary angiography as a gold standard, which report a significant decrease in specificity to 40 % or lower [19, 20] . However, there is good cause for optimism as these studies also suggest that FFR can be computed noninvasively based on anatomic knowledge of the CT scan (FFR-CT) resulting in much higher specificity while maintaining excellent sensitivity both across all patients and among those with intermediate lesions (30- 70 % luminal narrowing). Hence, adding information on physiological significance of stenosis has the potential to elevate CCT from a triage tool for the cath lab to a tool informing the decision to treat with optimal medical therapy (OMT) or to perform percutaneous coronary intervention (PCI).
Role of CCT in Acute Chest Pain
This is the most researched area, and several cohort and multicenter randomized studies have evaluated the role of CCT in acute chest pain. The Rule Out Myocardial Infarction using Computer-Assisted Tomography (ROMICAT I) trial is a large prospective observational cohort study, which rendered unbiased insights into the association of CCT findings with other diagnostic tests and clinical outcomes as the caregivers remained blinded to the results of CCT. Among the more eminent findings were that roughly half of the cohort had no CAD, 30 % had nonobstructive CAD, and 20 % had obstructive CAD. The absence of CAD had 100 % NPV for acute coronary syndrome (ACS), while only 50 % of obstructive lesions (>50 % luminal narrowing) were associated with ACS [21••] . Following ROMICAT I, several noncontrolled The ACRIN-PA trial formally confirmed this (0 % MACE; 95 % CI, 0 to 0.57). Across the trials, a significant reduction in length of stay, hospital admissions, and ED cost with a higher rate of invasive coronary angiography and PCI were observed. A major shortcoming is that we do not know whether the improved sensitivity for the detection of obstructive CAD by CCT and the subsequently increased number of PCI will also result in improved long-term health outcomes. Nevertheless, the reporting of these trials, especially ACRIN-PA and ROMICAT II, has established CCT as a viable alternative to functional testing.
Prognostic Value of CCT in Stable and Acute Chest Pain Syndromes
Data predominantly from retrospective studies and registries including well over 30,000 patients (Table 1) demonstrate that presence and extent of obstructive CAD is an independent predictor of mortality and cardiovascular events [25] [26] [27] [28] [29] [30] [31] [32] 
Prognostic Value of CT in Asymptomatic Adults
The utility of AS measurements in risk stratification of asymptomatic individuals has been investigated in several large prospective trials, and AS has added incremental value in Table 2 lists the major prospective cohort studies evaluating the ability of the AS to predict cardiovascular events [36] [37] [38] . Overall, these studies enrolled 11,000 patients between the ages of 59-71 who had 369 MACE (variably defined but including coronary Fig. 1 Description of the potential role of CCT in risk stratification and management of asymptomatic and symptomatic populations based on the currently available data [40] . Overall, all major studies established AS as an independent predictor of MACE in particular for coronary heart disease (CHD). Across the studies, this association was seen consistently for AS >100. However, the 10 % of the population with AS >300 is at a tenfold higher risk for MACE as compared to those without CACS adjusted for CVD risk factors and hence represents a group of asymptomatic individuals who would benefit from risk factor modification similar to secondary prevention. These results have led to incorporation of coronary artery calcification score (CACS) in the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines [41] and the appropriate use criteria [42] which both recommend that CACS may be appropriate to evaluate asymptomatic individuals at intermediate risk (10-20 % 10-year risk; class IIa indication) as well as in individuals with diabetes (class IIa indication). Hence, while there is evidence that non-contrast CT with very low radiation exposure (usually <1 mSv) may have a place in imaging of selected patients, the question remains whether this could be done in a costeffective manner. Of course, a randomized trial perhaps designed similarly to the Jupiter Trial [43] would be the ultimate study to assess the role of non-contrast CT imaging. Figure 1 describes the potential role of CCT in risk stratification and management of asymptomatic and symptomatic populations based on the currently available data. This figure will be informed by data from Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial, a prospective, randomized comparative effectiveness trial comparing CT angiography with functional testing for the occurrence of MACE over a median of 2 years.
Conclusions
Fifteen years after the introduction of multislice CT technology, high-quality research including large cohort studies in asymptomatic patients, registries for stable chest pain, and randomized trials for acute chest pain syndromes have established CCT as a valuable tool to noninvasively assess for coronary artery plaque and stenosis with the goal to improve risk stratification of both symptomatic and asymptomatic populations. Probably most established is the role of CCT in the early triage of patients with acute chest pain and the exclusion of significant stenosis in patients with stable chest pain syndrome. Most promising is the addition of functional or physiological information such as FFR-CT to the anatomic information. Research is needed to determine whether this would elevate CCT from a triage tool to decision tool for treatment of patients with obstructive CAD with OMT vs. PCI noninvasively. Overall, more work is needed to determine whether CCT in asymptomatic and symptomatic individuals for risk stratification and treatment will save lives in a costeffective manner, for example, via a decrease in invasive coronary angiography and revascularization.
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